why Sotera Health Company [SHC] is a Good Choice for Investors After New Price Target of $24.75

Sotera Health Company [NASDAQ: SHC] slipped around -0.17 points on Friday, while shares priced at $16.92 at the close of the session, down -0.99%. The company report on August 4, 2022 that Sotera Health Reports Second-Quarter and First-Half 2022 Results.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.


Q2 2022 net revenues of $267 million increased 6%, compared to Q2 2021.

Q2 2022 net income of $30 million or $0.11 per diluted share, compared to net income of $43 million or $0.15 per diluted share in Q2 2021.

Sotera Health Company stock is now -28.15% down from its year-to-date (YTD) trading value. SHC Stock saw the intraday high of $17.32 and lowest of $16.82 per share. The company’s 52-week high price is 27.38, which means current price is +2.67% above from all time high which was touched on 06/06/22.

Compared to the average trading volume of 1.18M shares, SHC reached a trading volume of 731932 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Sotera Health Company [SHC]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SHC shares is $24.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SHC stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wolfe Research have made an estimate for Sotera Health Company shares, keeping their opinion on the stock as Peer Perform, with their previous recommendation back on June 09, 2022. While these analysts kept the previous recommendation, Wolfe Research raised their target price to Outperform. The new note on the price target was released on April 06, 2022, representing the official price target for Sotera Health Company stock. Previously, the target price had yet another drop from $34 to $22, while Jefferies kept a Hold rating on SHC stock.

The Average True Range (ATR) for Sotera Health Company is set at 0.63, with the Price to Sales ratio for SHC stock in the period of the last 12 months amounting to 5.27. The Price to Book ratio for the last quarter was 7.45, with the Price to Cash per share for the same quarter was set at 0.46. Price to Free Cash Flow for SHC in the course of the last twelve months was 40.43 with Quick ratio for the last quarter at 2.50.

How has SHC stock performed recently?

Sotera Health Company [SHC] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.37. With this latest performance, SHC shares dropped by -7.89% in over the last four-week period, additionally sinking by -12.65% over the last 6 months – not to mention a drop of -33.59% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SHC stock in for the last two-week period is set at 31.19, with the RSI for the last a single of trading hit 24.85, and the three-weeks RSI is set at 35.45 for Sotera Health Company [SHC]. The present Moving Average for the last 50 days of trading for this stock 18.98, while it was recorded at 17.02 for the last single week of trading, and 20.75 for the last 200 days.

Sotera Health Company [SHC]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Sotera Health Company [SHC] shares currently have an operating margin of +32.25 and a Gross Margin at +48.84. Sotera Health Company’s Net Margin is presently recorded at +12.38.

Return on Equity for this stock inclined to 22.22, with Return on Assets sitting at 4.16.

Sotera Health Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.50 and a Current Ratio set at 2.80.

Earnings analysis for Sotera Health Company [SHC]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SHC. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sotera Health Company go to 27.55%.

Insider trade positions for Sotera Health Company [SHC]

There are presently around $4,237 million, or 89.30% of SHC stock, in the hands of institutional investors. The top three institutional holders of SHC stocks are: WARBURG PINCUS LLC with ownership of 105,417,315, which is approximately 0% of the company’s market cap and around 0.70% of the total institutional ownership; GTCR LLC, holding 70,278,209 shares of the stock with an approximate value of $1.19 billion in SHC stocks shares; and BLACKROCK INC., currently with $188.77 million in SHC stock with ownership of nearly 78.437% of the company’s market capitalization.

Positions in Sotera Health Company stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 112 institutional holders increased their position in Sotera Health Company [NASDAQ:SHC] by around 12,475,162 shares. Additionally, 69 investors decreased positions by around 8,938,768 shares, while 18 investors held positions by with 229,005,934 shares. The mentioned changes placed institutional holdings at 250,419,864 shares, according to the latest SEC report filing. SHC stock had 52 new institutional investments in for a total of 1,395,425 shares, while 17 institutional investors sold positions of 1,224,534 shares during the same period.


Please enter your comment!
Please enter your name here